Table 3 Summary of PK parameters (primary PK population).

From: ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

 

ATX-101 20 mg/m2

ATX-101 30 mg/m2

ATX-101 45 mg/m2

ATX-101 60 mg/m2

Parameter (unit)

n

Value

n

Value

n

Mean (SD)

n

Mean (SD)

AUC0-inf (h × ng/mL)

0

N/A

1

2080

4

2200 (591)

6

3700 (1220)

AUC0-t (h × ng/mL)

1

666

1

1900

4

1980 (427)

8

3320 (1260)

Cmax (ng/mL)

1

468

1

720

4

1150 (166)

8

1320 (815)

kel (/h)

0

N/A

1

1.81

4

2.25 (1.57)

6

1.51 (0.46)

CL (mL/h/m2)

0

N/A

1

14,400

4

21,500 (6120)

6

17,800 (5880)

Vz (mL/m2)

0

N/A

1

7970

4

13,100 (6830)

6

12,900 (5520)

MRT0-inf (h)

0

N/A

1

0.611

4

0.889 (0.393)

6

1.54 (0.66)

Cmax/D (m2 × ng/mL/mg)

1

23.4

1

24

4

25.6 (3.68)

8

22 (13.6)

AUC0-inf/D (h × [ng/mL] × m2/mg)

0

N/A

1

69.5

4

49.3 (13.1)

6

61.7 (20.4)

AUC0-t/D (h × [ng/mL] × m2/mg)

1

33.3

1

63.5

4

44 (9.49)

8

55.4 (21.1)

t1/2 el (h) Median [Min;Max]

0

N/A

1

0.38 [N/A]

4

0.45 [0.19;0.87]

6

0.48 [0.31;0.70]

tmax (h) Median [Min;Max]

1

2.02 [N/A]

1

2.98 [N/A]

4

2.37 [1.32;2.82]

8

4.75 [1.60;9.12]

tlast (h) Median [Min;Max]

1

2.17 [N/A]

1

3.32 [N/A]

4

2.77 [2.25;3.82]

8

5.13 [3.23;9.62]

  1. AUC area under the curve (0-t: from infusion start to the last measurable concentration, 0-inf from infusion start extrapolated to infinity), Cmax maximum plasma concentration, kel elimination rate constant, CL clearance, Vz volume of distribution, MRT mean residence time, D dose, t1/2 el elimination half-life, tmax time from infusion start to maximum plasma concentration, tlast time from infusion start to last plasma drug concentration assessment, SD standard deviation.